- Home
- CTNM vs USBC Comparison
CTNM vs USBC Comparison
Compare CTNM & USBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- USBC
- Stock Information
- Founded
- CTNM 2009
- USBC N/A
- Country
- CTNM United States
- USBC
- Employees
- CTNM N/A
- USBC 6
- Industry
- CTNM
- USBC
- Sector
- CTNM
- USBC
- Exchange
- CTNM Nasdaq
- USBC Nasdaq
- Market Cap
- CTNM 328.1M
- USBC 317.2M
- IPO Year
- CTNM 2024
- USBC N/A
- Fundamental
- Price
- CTNM $10.93
- USBC $0.75
- Analyst Decision
- CTNM Strong Buy
- USBC
- Analyst Count
- CTNM 5
- USBC 0
- Target Price
- CTNM $20.40
- USBC N/A
- AVG Volume (30 Days)
- CTNM 166.5K
- USBC N/A
- Earning Date
- CTNM 10-30-2025
- USBC N/A
- Dividend Yield
- CTNM N/A
- USBC N/A
- EPS Growth
- CTNM N/A
- USBC N/A
- EPS
- CTNM N/A
- USBC N/A
- Revenue
- CTNM N/A
- USBC N/A
- Revenue This Year
- CTNM N/A
- USBC N/A
- Revenue Next Year
- CTNM N/A
- USBC N/A
- P/E Ratio
- CTNM N/A
- USBC N/A
- Revenue Growth
- CTNM N/A
- USBC N/A
- 52 Week Low
- CTNM $3.35
- USBC N/A
- 52 Week High
- CTNM $16.25
- USBC N/A
- Technical
- Relative Strength Index (RSI)
- CTNM 47.95
- USBC 39.03
- Support Level
- CTNM $10.46
- USBC $0.71
- Resistance Level
- CTNM $13.09
- USBC $0.84
- Average True Range (ATR)
- CTNM 0.98
- USBC 0.08
- MACD
- CTNM 0.08
- USBC -0.01
- Stochastic Oscillator
- CTNM 29.68
- USBC 8.89
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About USBC USBC Inc.
USBC Inc is a non-invasive medical diagnostics. The group is focused on the development and commercialization of proprietary sensor technology utilizing radio and microwave dielectric spectroscopy. Its Sensor technology elicits a dielectric response that is different for every molecule. The group considers the business to currently have one operating segment: the development of its radio frequency spectroscopy technology, with a first focus on non-invasively ascertaining blood glucose levels.